Q32 Bio Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology company founded in 2017 and headquartered in Waltham, Massachusetts, develops biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to restore healthy immune balance in patients with severe autoimmune and inflammatory diseases. The company's lead product candidate, bempikibart (ADX-914), is a fully human anti-interleukin-7 receptor alpha (IL-7Rα) antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling; it is currently advancing in a Phase 2 program, including the ongoing SIGNAL-AA Phase 2a trial, for alopecia areata, following promising Phase 2a results showing clinical activity, biomarker inhibition, and a well-tolerated safety profile, with U.S. FDA Fast Track designation. Additional pipeline assets include the complement inhibitor platform featuring development candidate ADX-096, a C3d-CR1 fusion protein, alongside earlier-stage C3d monoclonal antibody fusions and nanobodies for tissue-targeted complement inhibition in renal and other complement-mediated diseases such as lupus nephritis, immunoglobulin A nephropathy, and complement component 3 glomerulopathy. Q32 Bio operates primarily in the United States, targeting patients with high unmet needs in T cell-mediated and complement-driven pathologies. In March 2024, the company completed a merger with Homology Medicines Inc. and a concurrent $42 million private placement financing with investors including OrbiMed, Atlas Venture, Abingworth, and Bristol Myers Squibb, providing cash reserves to fund operations through mid-2026 and enabling public trading under the QTTB ticker; formerly known as Admirx Inc., it changed its name to Q32 Bio in April 2020.
Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts
Q32 Bio Announces $55 Million Private Placement Financing
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive
Best Momentum Stocks to Buy for March 27th
New Strong Buy Stocks for March 27th
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Best Momentum Stocks to Buy for March 19th
New Strong Buy Stocks for March 19th
Best Momentum Stocks to Buy for March 13th
Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
New Strong Buy Stocks for March 13th
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Q32 Bio Announces $10.5 Million Registered Direct Offering
Dow Dips 200 Points; Q32 Bio Shares Jump